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ABSTRACT 
Background: In patients with rectal cancer, ‘watch-and-wait’ (W&W) for clinical complete 
response (cCR) following neoadjuvant chemo-radiotherapy is a novel management strategy 
with potential to avoid major surgery. Study-level meta-analyses report wide variation in local 
regrowth rates. We performed an individual participant data (IPD) meta-analysis to evaluate 
factors influencing local regrowth occurrence as a potential explanation of this variation.  
Methods: We updated a recent systematic review search (MEDLINE and Embase, from 01 
Jan 2016 to 05 May 2017; plus expert knowledge) to identify published studies in patients 
with rectal cancer reporting local regrowth following W&W for cCR following neoadjuvant 
chemo-radiotherapy. We restricted studies to those that defined cCR using criteria 
equivalent to São Paulo benchmarks, and requested IPD. We assessed study quality using 
an 11-item checklist. The primary outcome was 2-year local regrowth cumulative incidence 
estimated using a two-stage random-effects (RE) IPD meta-analysis. We evaluated the 
impact of clinical and treatment factors using Cox frailty models, expressed as hazard ratios 
(HRs). From these models, we derived percentage differences in mean theta as an 
approximation of the impact of measured covariates on between-centre heterogeneity. 
Results: We obtained IPD from 10 studies (11 datasets), totally 602 patients enrolled 
between 11 March 1990 and 13 February 2017, with a median follow-up of 37.6 (IQR: 25.0 – 
58.7) months. Ten of the 11 studies were judged to be at low-risk of bias. There was wide 
between-centre variation in patient, tumour and treatment characteristics. The 2-year local 
regrowth cumulative incidence was 21.4% (RE 95% CIs: 15.3-27.6) with high levels of 
between-study heterogeneity (I2 = 61%). There was some evidence that increasing cT stage 
was associated with increased risk of local regrowth (RE HRper cT stage: 1.395, Ptrend = 0.048). 
In a sub-cohort of patients managed post-2008 (after which high-resolution MR pre-
treatment staging became standard), 2-year local regrowth cumulative incidences were 19% 
(95% CIs: 13-28) for cT1/cT2, 31% (95% CIs: 26-37) for cT3, and 37% (95% CIs: 30-60) for 
cT4 (RE HRper cT stage: 1.482, Ptrend = 0.033). We estimated that measured factors contributed 
4.8% to 45.3% to the explanation of observed between-centre heterogeneity.  
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Interpretation: Among patients with rectal cancer and cCR managed by W&W, there was 
some evidence that increasing cT stage predicts for local regrowth. These data will inform 
clinician-patient decision-making in this setting. There is a research need to determine other 
predictors of a sustained clinical complete response.  
Funder: None. 
Registration: PROSPERO CRD42017070934 
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Research in context 
Evidence before this study 
In patients with rectal cancer who achieve a complete clinical response (cCR) after 
chemo-radiotherapy, the strategy of watch and wait (W&W) is new and offers an 
opportunity for patients to avoid major resection surgery. However, in the absence of 
randomised trials, this approach is not standard care. One recently published study-level 
meta-analysis of 23 studies (published and unpublished) including 871 patients, evaluated 
the outcome of patients managed by W&W and estimated a 2-year local regrowth rate of 
15.7% but noted considerable between-study heterogeneity (I2 = 55.9%), with rates 
ranging from 3.3% to 33.3%. A second updated study-level meta-analysis of 17 published-
only studies (692 patients) reported a 3-year cumulative risk of local regrowth of 21.6% (I2 
= 66.5%). A register-based project, the International Watch and Wait Database (IWWD), 
reported on 880 patients with cCR managed by W&W, from 47 participating institutes (15 
countries) and estimated a 2-year local regrowth cumulative incidence of 25.2%. 
Understanding factors that predict for local regrowth might explain the reported high levels 
of between-study heterogeneity. To-date, there is no large-scale study that has evaluated 
predictive factors for local regrowth because the study-level meta-analyses were unable to 
extract these data in an analysable form and there was considerable missingness in the 
IWWD registry-based report. 
Added value of this study 
This is the first reported individual participant data (IPD) meta-analysis in this field. By 
using the IPD methodology, there were two main advantages over study-level meta-
analyses. First, we were able to test for predictive factors of local regrowth. And second, 
by incorporating Cox frailty models, we accounted for unmeasured factors at each study 
level. These factors might include centre-level protocols for staging, treatment, and follow-
up. We obtained data from 10 studies (11 datasets) totally 602 patients, and with a 
median follow-up of 37.6 months, we estimated that the 2-year local regrowth cumulative 
incidence was 21.4%. There was some evidence that increasing cT stage was associated 
with increased risk of local regrowth, an association that remained after adjustments. We 
tested for other predictors including age, gender, cN stage, tumour distance to anal verge, 
serum CEA, radiotherapy dose, and time to W&W decision, and found no associations.  
Implications of all the available evidence 
The current literature notes wide variation in local regrowth rates after initial W&W and 
raised the concern that this strategy might not be generalisable to standard care. The 
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present analysis exploited this heterogeneity of outcomes and demonstrated that the latter 
is partly explained by differences in study baseline characteristics. For the first time at-
scale, the present analysis shows that increasing cT stage is associated with increased 
risk of subsequent local regrowth. In a sub-cohort of patients managed after 2008 
(reflecting current standard practice using high-resolution MR pre-treatment staging), 2-
year local regrowth cumulative incidences were 19% for cT1/T2, 31% for cT3, and 37% for 
cT4. These estimates will inform clinician-patient decision making and future trials in the 
field of organ-preservation in patients with rectal cancer. 
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INTRODUCTION 
Surgical resection is the mainstay of treatment for rectal cancer.1 In patients who receive 
pre-operative neoadjuvant chemo-radiotherapy, up to a quarter have complete tumour 
regression, recognisable as a clinical complete response (cCR).2 In these patients, ‘watch-
and-wait’ (W&W) is a novel management strategy with potential to avoid major pelvic 
surgery.3 This strategy originated from Habr-Gama and colleagues4-6 in São Paulo, Brazil, 
over a decade ago, and extended, for example, to a large single institute series in the 
Netherlands7, 8 and to a multi-centre network coordinated through Manchester in the North 
West of England and Wales (the OnCoRe project).2 In a matched analysis of the OnCoRe 
data, survival rates were not inferior to those treated by standard surgical resection. 
Nonetheless, W&W has yet to reach universal acceptance in oncology and is not standard 
care.   
In 2017, Dossa and colleagues9 reported a study-level meta-analysis of 23 studies 
(15 published; 8 unpublished) including 871 patients, quantifying the risk of tumour local 
regrowth with W&W management in the setting of cCR. They estimated a 2-year local 
regrowth rate of 15.7% but noted considerable between-study heterogeneity (I2 = 55.9%), 
with rates ranging from 3.3% to 33.3%.9 A second updated study-level meta-analysis from 
Dattani et al.10 identified 17 published-only studies (692 patients) and estimated a 3-year 
cumulative risk of local regrowth of 21.6%, again with high levels of heterogeneity (I2 = 
66.5%). Such between-study heterogeneity adds to concerns that W&W management, 
practiced as specialist centres, might not be generalisable to standard care. Alternatively, 
understanding factors that predict for local regrowth might explain the causes of between-
study heterogeneity, ultimately better informing clinical pathways.  
Here, we perform and report an individual participant data (IPD) meta-analysis, 
obtaining IPD from 10 published studies (11 datasets) within the International Complete 
Response (InterCoRe) consortium. The central aim was to evaluate for factors influencing 
local regrowth. The InterCoRe project parallels the International Watch and Wait Database 
(IWWD),11 which recently reported on 880 patients with cCR managed by W&W, from 47 
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participating institutes (15 countries) and estimated a 2-year local regrowth cumulative 
incidence of 25·2%.  
The IPD meta-analysis approach has several advantages over the study-level meta-
analyses reported by Dossa et al.9 and Dattani et al.10, and over the registry-based IWWD 
reported by van der Valk and colleagues.11 IPD afford the meta-analyst the opportunity to 
standardise inclusion criteria and analyses; obtain study results that had not been provided 
by the study publications; check modelling assumptions;12 and importantly, for this study, 
model data as time-to-event cumulative incidence rather than crude rates. In the IPD meta-
analysis framework, one models individual-level covariate-outcomes directly clustered within 
studies and minimises ecological bias compared with a meta-regression of aggregate data 
across studies.13 To-date, there is no large-scale study that has evaluated predictive factors 
for local regrowth because the study-level meta-analyses9, 10 were unable to extract these 
data in an analysable form and there was considerable missingness in the IWWD registry-
based report.11  
 
METHODS  
Reporting was in accordance with PRIMA-IPD recommendations,14 and the protocol was 
registered with PROSPERO (CRD42017070934).  
 
Eligibility and study selection 
The PICO (Population; Intervention; Comparator; Outcome) was as follows. We sought to 
identify studies of patients with locally advanced rectal cancer where the intervention was 
W&W after cCR following neoadjuvant chemo-radiotherapy, as the predominant treatment 
modality within each reported study, and followed-up to local regrowth, as defined by the 
2014 Champalimaud conference.15 We anticipated that the majority of studies would be 
treatment single-arm series, and accordingly, did not seek a comparator.  
 We used the systematic search published by Dossa and colleagues9 (as our PICO 
was equivalent) and updated using MEDLINE and Embase databases. From the main 
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searches, we took a cut of identified studies from 01 Jan 2016 to 05 May 2017, and with 
studies identified through expert knowledge, added these to the studies identified by Dossa 
et al.9 There was no language restriction. The search terms are detailed in webappendix p1. 
As the central theme was the evaluation of predictive factors, we sought to have a 
baseline ‘level playing field’ and only included studies where the definition of cCR was 
judged to have used criteria equivalent to those of the São Paulo benchmarks, described by 
Habr-Gama et al. in 20045 and 201016 – namely, absence of residual ulceration, stenosis, or 
mass within the rectum using clinical and endoscopic examination. As abstracts did not allow 
this assessment, we excluded a priori unpublished studies. While, the Habr-Gama ‘definition’ 
papers5, 16 restricted their cases to the distal rectum, subsequent large series,8, 17 the two 
meta-analyses9, 10 and the IWWD report11 included proximal rectal tumours. Thus, we did not 
restrict by tumour distance from the anal verge.  
 
Data collection and harmonisation  
We approached chief investigators for identified studies and transferred fully anonymised 
data in encrypted files under centre-level governance arrangements. Data harmonisation is 
detailed in webappendix p2. To ensure homogeneity of patients entering into W&W 
management, from the received datasets, we excluded those who received short course 
radiotherapy as initial treatment; those treated by local excision or contact brachytherapy as 
part of the initial W&W management; and patients with distant metastases at baseline. 
  
Risk of bias assessment in individual studies 
We assessed study quality, modifying the Institute of Health Economics Quality Appraisal 
(IHEQA) Checklist for Case Series Studies.18 This checklist comprises 18 ‘yes/no’ items, 
with explanatory dictionaries. Only the first 11 items were relevant as subsequent items 
relate to reporting qualities, which did not apply to the IPD meta-analysis framework. Studies 
were considered to have a low-risk of bias if at least 80% of criteria were met, moderate-risk 
if 60% to 79% of criteria were met, and high-risk if less than 60% of criteria were met. 
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Outcome measures  
The primary outcome was 2-year local regrowth cumulative incidence from date of W&W 
decision (we took this as equivalent to the date at which cCR was achieved). This allowed 
direct comparability with the aggregate-level meta-analysis from Dossa et al.9 Secondary 
outcomes were: local regrowth cumulative incidence at 1-, 3-, 4- and 5-years; proportion of 
patients with local regrowth undergoing salvage surgery and proportion R0 (negative 
resection margin); 5-year overall survival (OS); 5-year non-regrowth disease-free survival 
(nrDFS), as detailed in our previous work;2, 17 and 3-year distant metastasis rate, the latter 
three outcomes from date of first treatment. Post-protocol registration, we added 3-year 
post-salvage surgery survival, from date of salvage surgery. 
 
Statistical Analysis 
We used STATA version 14.0 (College Station, TX) in our analyses. For tables of study 
characteristics, we summarised proportions and medians (with inter-quartile ranges, IQRs) 
and compared with chi-squared and Kruskal- Wallis tests across studies. 
 To derive summary estimates of local regrowth cumulative incidences, we took two 
approaches. In our main model, we used a two-stage IPD approach; first undertaking time-
to-event analyses per dataset to determine 2-year local regrowth cumulative incidence with 
95% confidence intervals (95% CIs) using 1 – Kaplan-Meier (KM) analyses, and then 
combined the outputs using a random-effects methods with the admetan command. We 
assessed between-study heterogeneity with the I2 statistic and assigned adjective low, 
moderate and high for values close to 25%, 50%, and 75%, respectively.19 We repeated this 
for 1-, 3-, 4- and 5-year local regrowth cumulative incidences. For yearly summary 
estimates, we additionally derived prediction intervals. Second, we pooled data from all 
datasets and reported 1- through 5-year local regrowth cumulative incidence as 1 – KM and 
95% CIs, without accounting for within centre correlations. We denoted our main (preferred) 
analysis as ‘RE’ (random-effects); and our second analysis as ‘pooled’ analysis. 
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We evaluated the impact of clinical and treatment covariates on local regrowth. 
Initially, we reported univariable pooled analysis, and compared as required using log-rank 
tests. For multivariable modelling, we used Cox frailty models, with results expressed as 
hazard ratios (HRs) and their 95% CIs. These models introduce a random-effects approach 
to account for associations and unobserved heterogeneity due to participation of different 
centres.20 In the context of the present study, this approach takes account of unmeasured 
factors, sometimes called ‘noise’, at each study level such as centre-level protocols for 
staging, treatment, and follow-up. Frailty models are increasingly reported in multi-centre trial 
analyses to account for centre-level variations in clinical practice outside the trial protocol.21 
A limitation of the Cox frailty model occurs where one attempts to evaluate a predictor where 
certain values of that covariate exist only in specific centres. This is similar to the ‘co-
linearity’ problem in regression models. From Cox frailty models, we derived theta () values 
and their standard errors, and tested for  = 0 using the likelihood ratio test to quantify 
between-centre variability. P value < 0.01 was taken to mean that the correlation between 
participants within centres could not be ignored. To approximate the impact of measured 
factors on between-centre heterogeneity, we performed frailty models with and without 
covariates, and derived percentage mean differences in theta values. We tested 
assumptions of proportionality using Schoenfeld residuals and visualising predicted versus 
observed survival plots. 
There were 20 core variables. Missingness was generally low. Data were complete 
for age and gender, and missing in 4.3% for cN stage; 7.6% for cT stage (none from one 
small study22); and 7.6% for tumour distance to anal verge (AV), which formed the basis for 
multivariable model A (10 datasets). Time to decision for W&W was not calculable for the 
two São Paulo datasets – thus, model B was model A plus time to decision for W&W based 
on 8 datasets. Serum CEA values were missing in 45.3% - thus, model C was model A plus 
serum CEA. Radiotherapy dose was missing in only 6.5% - but was near totally coincident 
with centre status (the co-linearity problem mentioned above), this was reported only in 
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univariable models. In multivariable models, the continuous variable, time to decision for 
W&W and serum CEA were modelling using fractional polynomials.23 
For reporting proportions among patients undergoing salvage surgery, we used a 
two-stage IPD approach, first estimating proportions (using the metaprop command) with 
95% CIs, and then combined using a random-effects methods. For the outcomes of OS, 
nrDFS and distant metastases, we used similar two-stage meta-analysis approaches as 
those for local-regrowth cumulative incidence. 
For interpretation of statistical significance, we used the language recommended by 
Pocock and Ware,24 namely: ‘weak evidence’ for 0.05 < p < 0.10; ‘some evidence’ for 0.01 < 
p < 0.05; and ‘strong evidence’ for p < 0.001. 
 
Post-protocol stratified analysis 
After full data collection, it became clear that enrolment dates ranged from 11 March 1990 to 
13 February 2017; older than anticipated in the initial protocol. We posseted at there was 
risk of misclassification in pre-treatment staging across such a long period, and thus, we 
performed a post-protocol stratified analysis limited to patients enrolled into studies after 01 
January 2008. We judged this to reflect contemporary clinical practice where pre-treatment 
staging is generally by high-resolution MR evaluation using the MERCURY study25 
principles. 
 
Publication bias, data availability bias and reviewer selection bias 
We assessed for publication bias using contour enhanced funnel plots and the asymmetry 
test in accordance with recommendations from Sterne et al.26 As per principles set out by 
Ahmed et al.,27 we assessed for data availability bias (IPD not available  - e.g. unpublished 
but available as summary estimates in abstract form) by adding summary estimates from 
abstracts (from the Dossa et al.9 meta-analysis) and comparing with our summary estimates 
for the IPD data. Similarly, we assessed for reviewer selection bias (IPD only sought from a 
subset of known studies) by adding summary estimates of other known published studies 
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(taken mainly from the Dossa et al.9 meta-analysis as 2-year local regrowth was also primary 
outcome) and comparing with our summary estimates for the IPD data.  
 
Role of the funding source 
There was no funder of this study. Five members (SC, LM, JE, RR, AGR) of the writing sub-
group had access to all the data. Senior members (SC, RR, GB, RP, AGR) of the writing 
sub-group shared the responsibility for the final decision to submit the report for publication. 
 
RESULTS 
Included studies 
The flow diagram of the search, study identifications, and reasons for not including studies 
are detailed in webappendix p3-5. We initially received data from 11 studies, but excluded 
one study28 where all patients received contact Papillon brachytherapy. For the large São 
Paulo series, we judged that there were two distinct cohorts – patients in the early series 
(denoted as São Paulo  I), which were referred from two centres (University of São Paulo; 
Angelita & Joaquim Gama Institute, AJGI) and received neoadjuvant chemo-radiotherapy as 
50.4 Gy and 2 cycles of 5-fluorouracil;6 whereas the later series (denoted as São Paulo II) 
was treated from the outset through the AJGI, with an extended regimen of 54 Gy and 6 
cycles of 5-fluorouracil.6  
Our final analysis was from 10 studies (11 datasets).2, 4, 6, 8, 22, 29-34 We judged that the 
definitions for cCR, across all datasets were equivalent to São Paulo benchmarks5, 16 
(evidenced in webappendix p6-7). The total number for analysis was 602 patients – 108 
were not reported in previous publications. We noted two clinical indications among the 
studies: those termed standard practice neo-adjuvant chemoradiotherapy where cCR rates 
ranged from 12% to 49%, and two studies where there was an intentional enhanced cCR 
ranging from 68%29 to 73%4 (webappendix p8).  
 
Study characteristics 
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Patient, tumour and treatment characteristics, by dataset, are summarised in Table 1. There 
was wide variation in characteristics and pathways: for example, median ages ranged from 
59 to 75 years (p = 0.0001); proportion of men ranged from 40% to 91% (p = 0.001)); 
median tumour distance to AV from 3 to 6 cm (p = 0.0001); proportion of combined cT3/ cT4 
stage from 43% to 83% (p = 0.007); and proportion of cN+ stage from 13% to 76% (p < 
0.0001); and median time to W&W from 6 to 17 weeks (p = 0.0001). There were differences 
in radiotherapy treatment protocols – for example, for larger series, the radiotherapy dose 
regimen was predominantly 45 Gy in OnCoRe;2 predominantly 50.4 Gy in Maastricht;8 
mainly 45 Gy and 50.4 Gy in São Paulo  I;16 mainly 54 Gy in São Paulo  II;6 and exclusively 
60 Gy in Vejle.29 Concurrent chemotherapy (5-fluorouracil-based in 518 out of 570 or 91%) 
was used in all series, and was used at least 95% of patients in seven datasets. 
 
Assessment of Study Methodological Quality 
Using the IHEQA Checklist,18 ten of the 11 studies were judged to be at low-risk; one study8 
was judged to be moderate-risk of bias (webappendix p9). 
 
Local regrowth 
Overall, median follow-up was 37.6 (IQR: 25.0 to 58.7) months, but between studies, median 
follow-up ranged from 12.4 to 60 months. There were 166 local re-growths (crude proportion: 
27.6%). The summary 2-year local regrowth cumulative incidence was 21.4% (RE 95% CIs: 
15.3-27.6). There was a were high level of between-study heterogeneity (I2 = 61%) (Figure 
1).  
In the pooled analysis, the 1-, 2-, 3-, 4- and 5-year local regrowth rates were: 17.6% 
(95% CIs: 14.8-20.9), 24.7% (95% CIs: 21.4-28.5), 28.1% (95% CIs: 24.5-32.1), 31.1% (95% 
CIs: 27.2-35.5), and 31.6% (95% CIs: 27.6-36.0), respectively (Figure 2A). By contrast, for 
2-stage random-effects meta-analysis, summary point estimates for years 1 to 5 were more 
conservative at 15.6% (95% CIs: 9.9-21.4), 21.4% (95% CIs: 15.3-27.6), 24.9% (95% CIs: 
18.5-31.3), 27.3% (95% CIs: 19.8-34.8), and 28.0 (95% CIs: 20.3-35.8), but with wider 95% 
16 
 
CIs (Figure 2B). Local regrowth occurred almost exclusively in the first three years (155 out 
of 166 or 93.4%). We assessed visually for proportionality of local regrowth curves with time 
across the 11 datasets, and found similar patterns in all datasets (webappendix p10). 
 
Cox frailty models 
We tested for factors predicting local regrowth, initially for the total cohort, and then as a 
post-2008 sub-cohort analysis (Table 2). For the total cohort, there was some evidence that 
increasing cT stage was associated with increased risk of local regrowth. By univariable 
analysis, 2-year cumulative incidences were 18% (95% CIs: 13-25) for cT1/T2, 29% (95% 
CIs: 24-34) for cT3, and 31% (95% CIs: 17-52) for cT4. In the multivariable frailty model, 
including age, gender, CT stage, N stage and distance to AV (model A), the HR per cT stage 
increase was 1.395 (RE 95% CI: 1.002, 1.941, Ptrend = 0.048). There were no associations 
among other factors in model A (10 studies), model B (8 studies; incorporating time to W&W 
decision) or model C (8 studies; incorporating serum CEA).  
For the sub-cohort of patients managed after 2008, 2-year local regrowth cumulative 
incidence increased in a stepwise manner from 19% (95% CIs: 13-28) for cT1/cT2, 31% 
(95% CIs: 26-37) for cT3, to 37% (95% CIs: 30-60) for cT4. In model A, the HR was per cT 
stage increase was 1.496 (RE 95% CI: 1.032, 2.168, Ptrend = 0.033).  
We tested (likelihood ratio test) for  = 0 and found statistical significance in all 
models, indicating that correlation within centres could not be ignored (Table 3). We 
compared theta values in each model (A to C) with and without added factors, and noted 
that the likelihood ratio test remained statistically significant and that the addition of the 
measured factors only modestly influenced theta. We estimated that this contribution ranged 
from 4.8% to 45.3%.  
 
Salvage surgery 
Of the 166 patients with local regrowth, salvage surgery was performed in 137 (RE estimate: 
89%, 95% CIs: 80-98), of which R0 status was achieved in 131 (RE: 98%, 95% CIs: 95-100) 
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(Table 4). After histopathological examination, only four patients were pT4; the majority (59 
patients) were pT3 (RE: 44%, 95% CIs: 30-58). Node positivity was noted in 18 resections 
(RE: 16%, 95% CIs: 5-27).  
 The 137 patients with local regrowth undergoing salvage surgery were younger than 
the 29 patients treated by non-surgical strategies [median (IQR) age: 65.2 (57.4-71.2) versus 
70.3 (60.9-76.0) years, p = 0.037). The commonest reason for no salvage surgery was 
synchronous distant metastases (12 patients) or unfit, mainly associated with older age (10 
patients aged 75 years or older). The 3-year post-salvage survival rate was 80.1% (95% CIs: 
70.3-87.0); the 3-year survival in patients not undergoing salvage surgery was 55.3% (95% 
CIs: 30.0-74.8) (webappendix p11). Accounting for age at local regrowth and between-centre 
variation, this was not statistical different (p = 0.153). 
 
Survival and distant metastases rates 
There were 68 deaths. The 5-year OS rate was 87.0 (RE 95% CIs: 81.5-92.4); and the 5-
year nrDFS rate was 81.3% (RE 95% CIs: 74.9-87.6) (webappendix p12). Distant 
metastases were reported in 60 patients. The 3-year distant metastasis rate was 9.1% (RE 
95% CIs: 8.7-9.5). The commonest sites of distant metastases were lung (31 of 60 patients) 
and liver (23 of 60 patients) (webappendix p13). Approximately half patients (31 of 60 
patients) with distant metastases had local regrowth – these were identified synchronous 
with local regrowth in 12 patients; after local regrowth in 14 patients; and before local 
regrowth in only four.  
 
Publication, data availability and reviewer selection biases 
We visually inspected for asymmetry in the funnel plot for the 11 included datasets and 
found no evidence indicating publication bias (webappendix p14). For the primary outcome 
of 2-year local regrowth cumulative incidence, we found no evidence for data availability bias 
[RE: 21.4% (95% CIs: 15.1-27.7) versus 13.9% (95 CIs: 7.9-19.8), pinteraction = 0.111] 
18 
 
(webappendix p15) and weak evidence for reviewer selection bias [RE: 21.4% (95% CIs: 
15.1-27.7) versus 11.5% (95 CIs: 5.3-17.7), pinteraction = 0.089] (webappendix p16).  
 
DISCUSSION 
Summary of main findings 
We report five main findings. First, among studies of patients with rectal cancer and cCR 
managed by W&W, there was wide variation in baseline patient, tumour and treatment 
characteristics, but overall, the study quality was at low risk of bias. Second, the 2-year local 
regrowth cumulative incidence was approximately a fifth but there was wide variation across 
studies. Third, there was some evidence that increasing cT stage was associated with 
increased risk of local regrowth, particularly in sub-cohort of patients managed post-2008, 
but there was no clear signal of associations for other factors evaluated. Fourth, the 
observed between-study heterogeneity in local regrowth may partly be explained by study 
differences in measured factors, such as cT stage, but other unmeasured predictors might 
be relevant, and seeking these, should be a future research direction. Finally, we described 
several secondary outcomes, which will inform clinician-patient decision-making. These 
include that after tumour local regrowth, salvage rates were high, almost all achieved R0 
status, and 3-year post-salvage survival was favourable; distant metastasis rates were low; 
and overall survival rates were favourable.  
 
Context of other literature 
There have been two published study-level meta-analyses9, 10 and one large registry-based 
review11 estimating local regrowth rates, and one meta-analysis35 focusing on salvage in 
patients with local regrowth. Dossa et al.9 performed a meta-analysis of 23 studies 
(published and unpublished) in 867 patients, and like our study, identified wide variation in 
baseline characteristics, but the authors were unable to directly test for differences. By 
contrast, our analysis directly reported these - for instance, median ages varied across the 
studies by as much as 16 years; and proportion of cT3/cT4 tumours varied from 43%29 to 
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82%.32 Our findings concur with Dossa and colleagues9 that there was a wide variation on 2-
year local regrowth rates across studies. They reported a summary 2-year local regrowth 
rate of 15.7%, lower than our summary estimate of 21.4%. Our assessment of data 
availability bias suggests that this difference was mainly driven by the inclusion of eight 
unpublished abstracts in the Dossa review,9 but this difference was not statistically 
significant. 
Dattani et al.10 recently reported a study-level meta-analysis of 17 published-only 
studies in 692 patients. They reported a 3-year cumulative risk of local regrowth of 21.6%. 
This study did not have individual-level time to event data, but the investigators used a 
variety of methods to estimate numbers at risk at 3 years, thereby accounting for censoring. 
Thus, their estimate is broadly equivalent to our 2-year local regrowth cumulative incidence 
of 21.4%,  
The recent IWWD report11 was a registry-based pooled analysis of 880 participants 
from 47 centres (15 countries). There were data from five centres (AJGI; OnCoRe; 
Maastricht; Hospital Italiano, Buenos Ares; Vejle) from our IPD meta-analysis that 
contributed 552 participants to IWWD. Not unexpectedly, there were similar estimates for 
several outcomes, but not all. For IWWD11 versus InterCoRe: 2-year local regrowth 
cumulative incidence was 25.2 (95% CIs: 22.2-28.5) versus 21.4% (RE 95% CIs: 15.3-27.6); 
5-year OS was 84.7% (95% CIs: 80.9-87.7) versus 87.0% (RE 95% CIs: 81.5-92.4); and 3-
year distant metastasis rate was 8.1% (95% CIs: 6.2-10.5) versus 9.1% (RE 95% CIs: 8.7-
9.5). However, for patients with local regrowth, in the IWWD paper,11 against a background 
of missing data, the salvage surgery rate was estimated to be 69%; that for InterCoRe was 
89% (RE 95% CIs: 80-98). R0 status was attained in 88% for IWWD; and almost all salvage 
operations in InterCoRe (98% RE 95% CIs: 95-100). We added the new finding that 3-year 
post-salvage OS was 80.1%. We additionally reported the new finding that 5-year nrDFS 
was 81.3% (RE 95% CIs: 74.9-87.6), previously arguing that this is an informative outcome 
of disease control.17  
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Although, there were individual-level data in IWWD,11 the data were pooled without 
taking account of between-study differences, and with high proportions of missing data for 
key confounder like cT stage (18%), the IWWD analysis was unable to evaluate for 
predictive factors of tumour local regrowth. From our analyses, we observed some evidence 
that increasing cT stage was associated with increased risk of local regrowth, and 
observation that had been noted at smaller scale from the São Paulo series.36 
The systematic review of Kong et al.35 focused on the rate of salvage surgery among 
studies where patients were managed by W&W. They included nine studies (370 patients) of 
which 256 (69.2%) had sustained cCR. In their analysis, the salvage surgery rate was 
83.8%; the equivalent rate in our analysis was 89% (RE 95% CIs: 80-98). 
 
Limitations and strengths 
Our study has limitations. First, we did not collect data on surveillance protocols. The IWWD 
study11 reported wide variation in frequency and assessment tools, and in theory, this might 
contribute to the observed between-study heterogeneity in key outcomes. We broadly 
controlled for this using frailty models, which takes account of centre-level heterogeneity, 
such as follow-up protocols. Second, the IPD meta-analysis approach does not resolve that 
included studies might be susceptible to bias. We formally assessed for this and found the 
great majority of studies were low risk. Third, we only sought data from a subset of published 
studies. We assessed for reviewer selection bias and found only weak evidence. Fourth, we 
only approached investigators of published studies, and thus data availability bias might 
occur. Again, we assessed for this, and found no strong evidence.  
At first glance, a study weakness might be lack of a comparator group. There is 
debate what this comparator might be – from patients with rectal cancer undergoing 
resection surgery and found to have a pathological CR, to patients with a cCR and treated 
by surgery.9 We previously argued that choice of comparator group depends on the 
question.2 If the question is oncological safety, for example survival outcomes, the 
comparison group should be matched for key prognostic factors such as age, performance 
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status, and tumour stage to minimise selection bias. By contrast, the study aim here was to 
evaluate predictive factors for local regrowth, as these will inform clinical protocols. 
  Our analyses has several strengths. First, in contrast to study-level aggregate data 
meta-analyses,9, 10 we assessed for predictors of local regrowth. To minimise the concern of 
baseline misclassification of cCR and facilitate interpretation of our predictions, we restricted 
studies to those that defined cCR using criteria equivalent to São Paulo benchmarks. 
Second, in common with IPD meta-analyses, in general, our platform allowed us to update 
and extend study-level information (for example, data on a sixth of participants were 
previously unreported); identify published studies which contained overlapping sets of 
participants; incorporated results from under-reported outcomes (for example, nrDFS17); 
verify results presented in the original study publications; standardised the strategy for 
statistical analysis; and assess model assumptions in each study. Specifically, we ran 
identical time-to-event analyses for each study, thus by-passing numbers at risk 
assumptions used in other meta-analyses. Third, we purposefully strengthened our 
analytical design seeking homogeneity of treatment – for example, some series8, 16 
historically included local excisions as part of the initial W&W management from an era 
when it was thought that this additional step was necessary. Similarly, we excluded patients 
with a ‘near complete’ clinical response,37 some of whom were treated by Papillon 
brachytherapy.38  
 
Clinical implications  
The first clinical question is whether our findings have identified a patient sub-group 
unsuitable for W&W. The answer is no. For example, although in the post-2008 sub-
analysis, cT4 tumours were associated with 2-year local regrowth cumulative incidence 
approximating 40%, there were still over half patients potentially benefiting from a sustained 
complete response. Going forward, there is a need to validate the associations between cT 
stage and local regrowth based on standardised MR-driven pre-treatment staging protocols. 
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The second clinical question is whether there should be a stratified approach to 
follow-up? Conceivably, one might argue that cT3 and cT4 tumours are at high-risk of local 
regrowth, but given the high salvage rates and attained R0 rates, it is questionable whether 
high-intensity surveillance in this patient sub-group would materially influence long-term 
outcomes. Similarly, the rate of distant metastases in all these patients is low, arguing that 
more regular CT surveillance is unlikely to make a major clinical impact.  
Finally, what are the implications for future trials? There are now several ongoing and 
in-development trials where rectal organ preservation is the primary motivation. Our study 
included one such trial;29 and the selection of patients in São Paulo  II cohort6 fulfil the same 
motivation. We showed that these sub-populations had similar local-regrowth rates as those 
achieving cCR through routine care. 
 
Unanswered questions and future research 
There are three key areas for research. First, there is a need to establish an internationally 
accepted definition of cCR, and in particular, establish the role of MR imaging in this 
definition. Second, there is a research need to determine other predictors of a sustained 
clinical complete response. There are several approaches including imaging, blood 
biomarkers, and tumour molecular phenotyping. Third, research is required to engage the 
options and preferences of patients. There is evidence that W&W is associated with 
substantially better quality of life and functional outcomes compared with the standard 
surgical resection.39 But, there is a major caveat that chemo-radiotherapy itself might be 
associated with long-term morbidity. In studies to-date, no study included MR-tailored 
approaches by surgery alone as a comparator. All three pathways (chemo-radiotherapy plus 
resection versus chemo-radiotherapy plus W&W versus tailored resection alone) need to be 
evaluated. Only then, can we truly appraise the role of W&W in the overall standard care 
management of locally advanced rectal cancer. 
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Table 1 Characteristics of 11 datasets of 602 patient with rectal cancer and cCR initially managed by watch and wait in the InterCoRe consortium 
 Totals Buenos 
Aires, 
Arg
34
 
Exeter, 
UK
32
 
Maas-
tricht, 
NL
8
 
NYU,  
US
31
 
OnCoRe, 
UK
2
 
Rio de 
Janeiro, 
Brazil
30
 
Sao    
Paulo I, 
Brazil
4
 
Sao 
Paulo II, 
Brazil
6
 
Taipei, 
Taiwan, 
China
22
 
Universit
y Penn, 
US
40
 
Vejle, 
DK
29
 
P values 
Number of patients 602 23 11 84 8 162 42 131 66 18 17 40  
Study period  2005-14 2006-12 2005-14 2005-15 2005-17 2002-14 1990-
2016 
2001-16 2008-11 2001-14 2010-14  
Median age (range) 
years 
64 
(30-89) 
75  
(31-89) 
64 
(47-81) 
63 
(33-84) 
63 
(52-82) 
67 
(41-88) 
64 
(43-81) 
62 
(30-86) 
59 
(31-82) 
64 
(35-86) 
63 
(43-81) 
68 
(46-86) 
0.0001* 
Men (%) 401 (67) 11 (48) 10 (91) 55 (66) 6 (75) 114 (70) 17 (40) 85 (65) 42 (64) 15 (83) 14 (82) 32 (80) 0.001† 
Median time to W&W 
(range) weeks 
11 
(8-15) 
11  
(8-16) 
12 
(11-16) 
12 
(8-20) 
8 
(6-19) 
11 
(10-14) 
17 
(10-26) 
Not 
available 
Not 
available 
8 
(7-9) 
12 
(6-19) 
6 
(6-6) 
0.0001* 
≥ 2 ECOG performance 
status (%) 
 Not 
available 
Not 
available 
Not 
available 
0 (0) 9 (6) 0 (0) Not 
available 
Not 
available 
Not 
available 
Not 
available 
Not 
available 
 
Median distance to AV 
(range) cm 
5  
(4-7) 
5  
(5-7) 
4  
(3-6) 
5  
(2-7) 
5  
(2-9) 
5  
(4-8) 
3  
(2-5) 
5  
(4-7) 
6  
(5-7) 
6  
(5-6) 
5  
(2-6) 
6 
(5-6) 
0.0001* 
Median serum CEA 
(range) ng/ml 
2.5 
(1.5-3.8) 
2.9 
(1.5-7.1) 
Not 
available 
2.1 
(1.2-3.6) 
3.0 
(1.6-3.0) 
2.9 
(2.6-4.0) 
2.4 
(1.6-4.5) 
2.0 
(1.4-2.9) 
2.2 
(1.4-4.8) 
1.6 
(1.0-2.2) 
5.6 
(3.2-7.4) 
Not 
available 
Not 
applicable 
cT stage              
   cT1 & cT2 (%) 163 (29) 6 (30) 2 (18) 22 (26) 2 (25) 38 (23) 8 (29) 34 (28) 25 (38) Not 
available 
3 (18) 23 (58)  
   cT3 & cT4 (%) 393 (71) 14 (70) 9 (82) 62 (74) 6 (75) 124 (77) 20 (71) 86 (72) 41 (62) Not 
available 
14 (83) 17 (43) 0.007‡ 
   Missing  3 0 00 0 0 14 11 0 18 0 0  
cN stage              
   cN0 (%) 228 (50) 9 (45) 4 (36) 20 (24) 3 (38) 51 (31) 26 (87) 89 (74) 39 (59) 13 (72) 11 (65) 23 (58)  
   cN+(%) 228 (50) 11 (55) 7 (64) 64 (76) 5 (63) 111 (59) 4 (13) 31 (26) 27 (41) 5 (28) 6 (35) 17 (43) < 0.0001‡ 
   Missing   3 0 0 0 0 12 11 0 0 0 0  
Radiotherapy dose 
regimens 
             
   45 cGy 212 (38) 5 3 1 1 153 5 29 0 14 1 0  
   50.4 cGy 228 (41) 18 1 83 6 6 37 68 1 0 8 0  
   54 cGy 79 (14) 0 0 0 1 2 0 7 64 4 1 0  
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   60 to 65 cGy 44 (8) 0 0 0 0 1 0 2 1 0 0 40  
   Missing 39 0 7 0 0 0 0 25 0 0 7 0  
Concurrent 
chemotherapy (%)  
570 (95) 23 (100) 8 (73) 84 (100) 7 (88) 143 (88) 40 (95) 126 (96) 66 (100) 18 (100) 15 (88) 40 (100) NA 
Chemotherapy 
regimens 
             
   5FU/ LV 66 (12) 0 0 0 0 0 0 0 66 0 0 0  
   Capecitabine 250 (44) 4 8 82 5 135 2 11 0 0 3 0  
   Infusional 5-FU 202 (35) 19 0 0 2 5 38 115 0 18 5 0  
   Oxaliplatin 9 (2)  0 0 2 0 0 0 0 0 0 7 0  
   Tegafurur 40 (7) 0 0 0 0 0 0 0 0 0 0 40  
   Others 3 (<1) 0 0 0 0 3 0 0 0 0 0 0  
Adjuvant chemotherapy 
(%) 
51 (8) 0 0 35 (42) 0 13 (8) 1 (2) 0 0 0 2 (12) 0 NA 
Median follow-up in 
months (IQR) 
37.6 
(25.0-58.7) 
36.2 
(36.2-36.2) 
60 
(38-81) 
38.4 
(24.7-57.6) 
12.4 
(10.4-52) 
36.9 
(22.8-53.1) 
50.4 
(32.7-63.8) 
49 
(18-86) 
41 
(25-58) 
33.7 
(25.4-52.6) 
60 
(35.4-91.8) 
35.5 
(25.6-42.2) 
 
Arg: Argentina. UK: United Kingdom. NL: the Netherlands. US: United States. NYU: New York University. Uni Penn: University of Pennsylvania. DK: Denmark. W&W: watch and wait.  
AV: Anal verge. CEA: carcinoembyronic antigen. 5-FU: 5-fluoruracil. 5-FU/ LV: Concomitant chemotherapy (5-FU - 450 mg/m
2
 and Leucovorin 50 mg fixed dose) delivered in a total of 6 cycles. 
NA: not applicable. IQR: inter-quartile range 
* Kruskal-Wallis test. 
† Chi-squared test. 
‡ Chi-squared test excluding missing data. 
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Table 2 Factors predicting local regrowth in patients initially managed by W&W in the InterCoRe consortium, accounting for centre 
effect in frailty models for the total cohort and post-2008 sub-cohort 
 
 Total cohort (n: 602) Post-2008 sub-cohort (n: 459) 
 IPD  
pooled 
analysis 
IPD frailty models 
 
 IPD  
pooled 
analysis 
IPD frailty models 
 
Univariable Multivariable* Univariable Multivariable* 
 No. of 
patients 
2-year local 
growth rate 
(95% CIs) 
Hazard ratio  
(95% CIs) 
Hazard ratio  
(95% CIs) 
No. of 
patients 
2-year local 
growth rate 
(95% CIs) 
Hazard ratio  
(95% CIs) 
Hazard ratio  
(95% CIs) 
All patients 602 25 (21-28)   459 27 (23-31)   
Age group         
  Per 10 years  602  1.007  
(0.876, 1.157) 
0.952 
(0.820, 1.106) 
459  0.924 
(0.786, 1.088) 
0.904 
(0.762, 1.072) 
Gender         
  Women 201 23 (18-30) 1.000 1.000 155 22 (16-30) 1.000 1.000 
  Men 401 25 (21-30) 1.165  
(0.835, 1.627) 
1.193 
(0.932, 1.056) 
304 29 (24-31) 1.439 
(0.972, 2.132) 
1.534 
(1.023, 2.298) 
cT-stage         
  cT1& cT2  163 18 (13-25) 1.000 1.000 125 19 (13-28) 1.000 1.000 
  cT3 367 29 (24-34) 1.400 
(0.963, 2.029) 
1.428 
(0.954, 2.137) 
282 31 (26-37) 1.553 
(1.009, 2.392) 
1.657 
(1.065, 2.579) 
  cT4 26 31 (17-52) 1.527 
(0.732, 3.185) 
1.864 
(0.840, 4.133) 
22 37 (21-60) 1.710 
(0.771, 3.794) 
1.904 
(0.849, 4.266) 
per cT stage 
increase 
  1.348 
(0.997, 1.822) 
1.395 
(1.002, 1.941) 
  1.454 
(1.039, 2.035) 
1.496 
(1.032, 2.168) 
cN-stage         
  cN0 288 25 (21-31) 1.000 1.000 192 28 (22-35) 1.000 1.000 
  cN+ 288 24 (19-30) 0.910 
(0.652, 1.270) 
0.869 
(0.607, 1.242) 
256 26 (21-32) 0.908 
(0.629, 1.309) 
0.751 
(0.512, 1.100) 
Distance to AV†         
  < 6.0 cm 311 25 (20-30) 1.000 1.000 264 27 (22-33) 1.000 1.000 
  ≥ 6.0 cm 246 23 (18-29) 0.937 
(0.666, 1.317) 
0.896 
(0.630, 1.273) 
160 23 (17-31) 0.810 
(0.549, 1.196) 
0.767 
(0.511, 1.153) 
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Serum CEA 
categories† 
        
  < 3.0 ng/ml 219 29 (23-35) 1.000  
 
Not included‡ 
164 32 (25-40) 1.000  
 
Not included‡ 
  3.0 to 9.9 ng/ml 88 19 (12-29) 0.704 
(0.422, 1.175) 
71 20 (13-32) 0.704 
(0.399, 1.243) 
  ≥ 10 ng/ml 22 36 (20-55) 1.544 
(0.790, 3.017) 
18 39 (30-65) 1.542 
(0.754, 3.155) 
Radiotherapy 
dose group 
        
   45 cGy 212 30 (24-37) 1.000  
 
Not appropriate¶  
187 33 (26-40) 1.000  
Not appropriate¶    50.4 cGy 228 19 (14-25) 0.899 
(0.563, 1.437) 
161 19 (13-26) 0.568 
(0.328, 0.985) 
   54 cGy 79 30 (21-42) 1.537 
(0.753, 3.140) 
38 40 (26-60) 1.492 
(0.740, 3.011) 
   60 to 65 cGy 44 26 (15-41) 0.989 
(0.409, 2.394) 
43 26 (15-42) 0.812 
(0.3622, 1.821) 
Intention to 
enhance cCR 
rate 
        
  Yes (2 centres) 106 26 (19-36) 1.000 Not appropriate¶ 67 28 (19-41) 1.000 Not appropriate¶ 
  No (11 centres) 496 24 (21-29) 1.126  
(0.573, 2.213) 
392 26 (22-31) 1.105 
(0.531, 2.296) 
         
Time to W&W¶¶         
   < 13 wks 264 23 (18-29) 1.000  
Not included‡ 
239 25 (20-33) 1.000  
Not included‡     ≥ 13 wks 141 25 (19-34) 1.211 
(0.805, 1.824) 
134 27 (20-36) 1.154 
(0.770, 1.730) 
         
CEA: carcinoembryonic antigen. AV: distance to anal verge. cT and cN staging according to AJCC 7
th
 edition. 
Analyses in post-2008 sub-cohort limited to model of age, gender, cT-stage, cN stage and distance to AV (equivalent to model A in Table 3) 
* For full cohort, the complete case multivariable model was based on 514 patienst, equivalent to model A in Table 3. For post-2008 cohort, the complete case multivariable 
model was based on 393 patients. 
† Categorisation cut-off points for serum CEA and distance to AV were based on clinical reasons. Distance to AV of 6cm was taken as equivalent to that commonly used to 
define low-rectal cancers. 
‡ Not included in multivariable model due to substantial proportion of missingness. 
¶ Not appropriate due to coincidence of radiotherapy dose and study centre. 
¶¶ Cut-off point of 13 weeks determined using spline approaches; equivalent to Model B in Table 3 
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Table 3 Outputs from frailty models clustering for centres and assessing changes in between-study heterogeneity (theta) for local 
regrowth, with and without covariates 
 
 Covariates in model No. of 
datasets 
No. of 
patients 
Mean theta,  
(se) 
% difference 
in theta 
Likelihood 
of theta = 0  
AIC 
TOTAL COHORT        
Model A        
No covariates none  
10 
 
514 
0.1190 (0.0954)  0.002 1673.7 
With 
covariates 
age, gender, cT stage, cN stage, 
distance to AV 
0.1248 (0.1013) 4.8% 0.003 1680.2 
Model B        
No covariates none  
8 
 
337 
0.1812 (0.1481)  0.001 981.5 
With 
covariates 
age, gender, cT stage, cN stage, 
distance to AV, time to W&W 
decision 
0.2633 (0.2134) 45.3% 0.001 978.3 
Model C        
No covariates none  
8 
 
278 
0.2662 (0.2054)  < 0.001 872.2 
With 
covariates 
age, gender, cT stage, cN stage, 
distance to AV, baseline serum CEA  
0.2465 (0.1921) 7.4% 0.001 870.9 
        
POST-2008 SUB-COHORT       
Model A        
No covariates none  
10 
 
393 
0.0964 (0.0776)  0.005 1234.4 
With 
covariates 
age, gender, cT stage, cN stage, 
distance to AV 
0.1084 (0.0851) 12.4% 0.003 1233.9 
        
 
W&W: watch and wait. Se: standard error. CEA: carcinoembyronic antigen. AV: anal verge. Distance to AV, time to W&W decision and serum CEA as continuous variables. 
Time to W&W decision as a spline pivoted as 13 weeks (determined from fractional polynomials) 
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Table 4 Treatment of 166 patients with local regrowth initially managed by W&W in the InterCoRe consortium 
  Post-salvage surgery pathology findings 
 N (%) Positive  
CRM 
Positive  
DRM 
ypT stage† 
T0/T1/T2/T3/T4/missing 
ypN stage† 
N0/N+/ missing 
      
No. of patients with local regrowth 166     
Non-surgical treatments 29* (17)     
Surgical treatments 137 (83)     
      
Operation types      
  Abdomino-perineal resection 73 (52) 4 0 1/7/22/35/2/6 56/9/8 
  Anterior resection 29 (21) 0 0 3/5/6/14/0/1 20/8/1 
  Hartmann’s procedure 4 (3) 0 1 0/0/0/3/0/1 2/1/1 
  Other radical operations 6 (4) 0 0 0/0/2/2/2/0 6/0/0 
  Transanal local excision or TEM 25 (18) Not 
applicable 
1 0/5/13/5/0/0 Not applicable 
Totals  4 2 4/17/43/59/4/8 84/18/10 
      
Total colostomies 80 (48)     
      
Values in parentheses are percentages and only cited if value greater than five.  
TEM: transrectal endoscopic micro-dissection. CRM: circumferential resection margin. DRM: distal resection margin. 
*Five patients had synchronous diagnoses of distant metastases. 
† The Taiwan study did not contribute to the pathological T and N staging. 
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FIGURE LEGENDS 
 
Figure 1 Forest plot of 11 datasets. Sorted by descending 2-year local regrowth cumulative 
incidences Summary estimate, 95% confidence intervals, and prediction intervals shown for 
random effects method, and restricted maximum likelihood estimators (reml). 
UK: United Kingdom. DK: Denmark. NYU NYC: New York University, New York City. Arg: 
Argentina. US: United States. NL: The Netherlands 
. 
 
Figure 2 A; pooled analysis with local regrowth cumulative incidence from 1 to 5 years, with 
95% CIs. B; 2-stage random-effect meta-analysis with summary estimates for 1- through 5-
years, with 95% CIs, and predictive intervals in green. 
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